Sygenx is positioned to identify and acquire promising regenerative therapies that are in development and available from an array of industry and academic sources.


Through a patented and proprietary process, the alpha-2-macroglobulin (A2M) is isolated and concentrated from your own blood to biologically bait and trap destructive enzymes found in your joint or disc space to facilitate a healthier environment for repair or regeneration.